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Abstract
Kawasaki disease is an acute febrile vasculitis of childhood that is associated with elevated 
production of inflammatory cytokines, causing damage to the coronary arteries. The production of 
proinflammatory cytokines and expression of adhesion molecules in human coronary arterial 
endothelial cells (HCAECs) is regulated by nuclear transcription factor- B (NF- B) activation. We 
have previously reported that the active form of vitamin D, 1 ,25-dihydroxyvitamin D3
(1 ,25-(OH)2D3), inhibits tumor necrosis factor-  (TNF- )-induced NF- B activation. In this study, 
we examined the anti-inflammatory effects of 1 ,25-(OH)2D3 on TNF- –induced adhesion 
molecule expression (vascular cellular adhesion molecule-1 (VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1)) and cytokine production (interleukin-6 (IL-6) and IL-8) in HCAECs. 
Pretreatment with 1 ,25-(OH)2D3 significantly inhibited TNF- –induced VCAM-1 expression and 
IL-8 production in HCAECs. Our results suggest that adjunctive 1 ,25-(OH)2D3 therapy may 
modulate the inflammatory response during Kawasaki disease vasculitis. 
Key words: Kawasaki disease; Coronary arterial endothelial cells; IL-8; VCAM-1; 
1 ,25-dihydroxyvitamin D3
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1. Introduction 
Kawasaki disease (KD) is an acute illness of early childhood that is characterized by prolonged fever, 
diffuse mucosal inflammation, persistent edema of the extremities, polymorphous skin rash, and 
non-suppurative lymphadenopathy [1]. Histopathology results show that patients display 
panvasculitis with endothelial necrosis, as well as infiltration of mononuclear cells into small and 
medium-sized blood vessels [2]. The primary and most significant complication of KD is coronary 
arterial lesions, which may cause significant coronary stenosis, resulting in ischemic heart disease [3]. 
In earlier studies, we showed that activation of nuclear transcription factor- B (NF- B), a 
transcription factor regulating the expression of proinflammatory cytokines, and tumor necrosis 
factor-  (TNF- ) activity play important roles in the pathogenesis of KD [4–8]. In addition, arterial 
endothelial cells are known to be activated in acute KD, because the levels of soluble forms of 
various adhesion molecules are elevated in the peripheral blood [9,10].  
The active form of vitamin D, 1 ,25-dihydroxyvitamin D3 (1 ,25-(OH)2D3) or calcitriol is 
associated with calcium and phosphorus homeostasis and maintenance of skeletal architecture [11]. 
Recently, several studies have reported that 1 ,25-(OH)2D3 exhibits anti-inflammatory and 
immunomodulatory effects [11–13]. TNF-  production and NF- B activation in macrophages, and 
TNF- –induced expression of intercellular adhesion molecule-1 (ICAM-1, CD54) and vascular 
cellular adhesion molecule-1 (VCAM-1, CD106) in human umbilical vein endothelial cells are 
inhibited by 1 ,25-(OH)2D3 [13–18]. These findings put forward the possibility that 1 ,25-(OH)2D3 
could be effective in treating endothelial cell inflammation in acute KD. In addition, approximately 
10% of KD patients are resistant to the standard high-dose intravenous immunoglobulin (IVIG) 
therapy, highlighting the need for new approaches [19,20]. In this study, we determined whether 
1 ,25-(OH)2D3 inhibits adhesion molecule expression (ICAM-1 and VCAM-1) and cytokine 
production (interleukin-6 (IL-6) and IL-8) induced by TNF-  in human coronary arterial endothelial 
cells (HCAECs).
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2. Materials and methods 
2. 1. Cell culture and stimulation conditions
HCAECs were obtained from Lonza (Walkersville, MD, USA) and maintained at 37°C under 
humidified 5% CO2 in a stationary culture. HCAECs were grown using the EGM-2 BulletKit 
(Lonza). The cells were grown in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) 
containing 10% fetal bovine serum (FBS; GIBCO), 100 units/mL penicillin (GIBCO), and 100 
g/mL streptomycin (GIBCO).  
HCAECs were exposed to 2 ng/mL TNF-  (R&D Systems, Minneapolis, MN, USA) with or 
without pretreatment with 1 ,25-(OH)2D3 (Wako Junyaku Co., Osaka, Japan) for 30 min. The cells 
and cell culture supernatants were collected 4, 8, 12, and 24 h after the addition of TNF-  for 
subsequent analysis.  
2. 2. Determination of ICAM-1 (CD54) and VCAM-1 (CD106) expression on HCAECs 
The expression of ICAM-1 and VCAM-1 was determined by flow cytometric analysis. The cells 
were then labeled with phycoerythrin-conjugated anti-ICAM-1 and anti-VCAM-1 antibodies 
(Becton-Dickinson Biosciences, San Diego, CA, USA). Immunofluorescence staining was analyzed 
with a FACSCalibur flow cytometer equipped with CellQuest software (Becton-Dickinson 
Biosciences). Five thousand cells were analyzed in the flow cytometric studies. 
2. 3. Determination of IL-6 and IL-8 production from HCAECs 
The concentrations of IL-6 and IL-8 in cell culture supernatants were determined with a 
sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, 
USA). The lower detection limits for IL-6 and IL-8 were 3.12 pg/mL and 31.2 pg/mL, respectively.  
2. 4. Real-time polymerase chain reaction (PCR) of VCAM-1 and IL-8 in HCAECs 
Real-time PCR was performed to determine the mRNA levels of IL-8 and VCAM-1 in HCAECs. 
Total cellular RNA was isolated using a QIAamp RNA Blood Mini Kit (Qiagen K.K., Tokyo, 
Japan), according to the manufacturer’s instructions. A critical RNA purification procedure was 
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performed with deoxyribonuclease (DNase) I (Invitrogen, Leek, The Netherlands) to eliminate 
DNA. Reverse transcription (RT) was carried out with 1 g of total RNA and oligo dT primers 
(Invitrogen) in a reaction volume of 20 L, using the SuperScriptTM First-Strand Synthesis System 
for RT-PCR (Invitrogen), according to the manufacturer’s instructions. Real-time PCR was carried 
out using TaqMan Gene Expression Assays and the StepOnePlusTM Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). IL-8 and VCAM-1 probes were purchased from 
Applied Biosystems. The PCRs were recorded and analyzed using the accompanying StepOneTM
software (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied 
Biosystems) served as the housekeeping gene for the reactions and the expression of the IL-8 and 
VCAM-1 genes was normalized to GAPDH. 
2. 4. Statistical analysis 
The data are presented as the mean ± standard deviation (SD). Statistical analyses were performed 
using unpaired Student’s t-tests, with p < 0.05 being considered as significant. Analyses and 
calculations were performed using SPSS-12.0 (SPSS Inc., Chicago, IL, USA). 
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3. Results 
3. 1. Inhibitory effects of 1 ,25-(OH)2D3 on TNF- –induced VCAM-1 expression  
Flow cytometric analysis revealed that TNF-  significantly increased VCAM-1 expression in 
HCAECs (p < 0.001; Figure 1). Pretreatment with 10-7 and 10-8 M 1 ,25-(OH)2D3 significantly 
inhibited TNF- –induced expression of VCAM-1 (p < 0.05), but pretreatment with 10-9 M had no 
effect. The kinetics of VCAM-1 expression in HCAECs pretreated with 1 ,25-(OH)2D3 prior to 
stimulation with TNF-  is shown in Figure 2. VCAM-1 expression was significantly inhibited 4 h 
after TNF-  stimulation (p < 0.05). Conversely, TNF-  treatment significantly increased ICAM-1 
expression in HCAECs (p < 0.001; Figure 3), whilst pretreatment with 1 ,25-(OH)2D3 had no effect 
4h (Figure 3) or 6h (data not shown) after stimulation.  
3. 2. Inhibitory effects of 1 ,25-(OH)2D3 on TNF- –induced IL-8 production  
Analysis of cell culture supernatants by ELISA demonstrated that TNF-  significantly increased 
IL-8 production in HCAECs (p < 0.001; Figure 4). Pretreatment with 10-8 M 1 ,25-(OH)2D3
inhibited TNF- –induced production of IL-8, but pretreatment with 10-7 and 10-9 M 1 ,25-(OH)2D3
had no effect (Figure 4). The kinetics of IL-8 production in HCAECs pretreated with 10-8 M 
1 ,25-(OH)2D3 prior to stimulation with TNF-  is shown in Figure 5. IL-8 production was 
significantly inhibited 4, 8, 12, and 24 h after TNF-  stimulation (p < 0.05, p < 0.05, p < 0.01, and p
< 0.05, respectively).  
Although TNF-  treatment significantly increased IL-6 production in HCAECs (p < 0.001; 
Figure 6), pretreatment with 1 ,25-(OH)2D3 did not inhibit the release of IL-6 (Figure 6).  
3. 3. Inhibitory effects of 1 ,25-(OH)2D3 on TNF- –induced VCAM-1 and IL-8 mRNA expression 
Real-time PCR demonstrated that pretreatment with 10-7 M and 10-8 M 1 ,25-(OH)2D3 inhibited 
TNF- –induced VCAM-1 mRNA expression 2 h and 4 h after TNF-  stimulation (p < 0.05, p < 
0.05, p < 0.05 and p < 0.05, respectively; Figure 7), but pretreatment with 10-9 M 1 ,25-(OH)2D3
had no effect (Figure 7). In addition, 10-7 M, 10-8 M and 10-9 M 1 ,25-(OH)2D3 had no inhibitory 
effects at 8 h after stimulation. Pretreatment with 10-8 M 1 ,25-(OH)2D3 inhibited TNF- –induced 
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IL-8 mRNA expression at 2h, 4h and 8h after stimulation (p < 0.05, p < 0.05 and p < 0.05, 
respectively; Figure 8), but pretreatment with 10-7 and 10-9 M 1 ,25-(OH)2D3 had no effect (Figure 
8).  
4. Discussion 
We previously demonstrated that NF- B was markedly activated in peripheral blood 
monocytes/macrophages and T cells from children with acute KD [7]. Serum TNF-  levels are 
elevated in KD; moreover, KD patients with high levels of soluble TNF receptor in the serum appear 
susceptible to coronary artery lesions [4–6,9]. NF- B is an essential transcription factor regulating 
genes that encode proinflammatory cytokines, chemokines, and adhesion molecules that mediate 
inflammation. The levels of VCAM-1 and ICAM-1, members of the immunoglobulin superfamily, 
and E-selectin are increased on endothelial cells after exposure to inflammatory cytokines such as 
TNF-  and IL-1  [18,21]. It is likely that TNF- , induced primarily by NF- B activation, causes 
systemic vasculitis associated with high levels of ICAM-1 and VCAM-1 expression in vascular 
endothelial cells during the acute phase of KD. 
It has been reported that 1 ,25-(OH)2D3 exhibits anti-inflammatory and immunomodulatory 
effects [11–13]. 1 ,25-(OH)2D3 inhibited the production of interferon-  and IL-12 in T cells; 
differentiation, maturation, activation, and survival in dendritic cells; and TNF-  production and 
NF- B activation in macrophages [14–17]. 1 ,25-(OH)2D3 inhibits the activation of NF- B and the 
production of IL-6, IL-8, and “regulated on activation normal T cell expressed and secreted” 
(RANTES) in human microvascular endothelial cells. Furthermore, it has been shown to inhibit the 
expression of ICAM-1 and VCAM-1 in human umbilical vein endothelial cells [13,18]. We have 
previously shown that both mRNA and protein levels of the vitamin D receptor are expressed in 
HCAECs, and that 1 ,25-(OH)2D3 inhibits TNF- –induced NF- B activation and E-selectin 
expression in HCAECs [22]. In the present study, pretreatment with 1 ,25-(OH)2D3 significantly 
inhibited TNF- –induced expression of VCAM-1 and production of IL-8 in HCAECs, but had no 
effect on the expression of ICAM-1 or production of IL-6. The concentrations of 1 ,25-(OH)2D3
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(10-9 to 10-7 M) used in our study are consistent with levels obtained in healthy human plasma after 
administration of a normal dose [23,24].  
Our results also showed that 1 ,25-(OH)2D3 inhibited TNF- –induced mRNA expression of 
VCAM-1 and IL-8 as shown in Figures 7 and 8. 1 ,25-(OH)2D3 is known to reduce the basal and 
TNF- –induced binding activity of activator protein-1 (AP-1) and NF- B to their response elements, 
and to consequently inhibit AP-1– and NF- B–dependent tissue factor expression in monocytic cells 
[25]. Docosahexaenoic acid inhibits the expression of both ICAM-1 and VCAM-1, but had a more 
pronounced effect on VCAM-1 expression [26]. Furthermore, it has been reported that the cis
elements located at the promoter region of the ICAM-1 and VCAM-1 genes are different [26–28]. 
The human ICAM-1 promoter contains binding sites for a number of transcription factors, including 
signal transducer and activator of transcription (STAT), NF- B, AP-1, and antioxidant response 
elements [27]. On the other hand, the human VCAM-1 promoter includes binding sites for NF- B, 
AP-1, GATA, and thyroid response elements [28]. IL-6 release has been found to be associated with 
NF- B activity, while IL-8 release more closely correlated with AP-1 activity [29]. We speculate 
that the differences in the inhibitory effect of 1 ,25-(OH)2D3 on VCAM-1 and ICAM-1 expression, 
and IL-8 and IL-6 production in TNF- –induced HCAECs, result from the complicated 
transcriptional regulation of these genes.  
Recently, it has been reported that 1 ,25-(OH)2D3 may be used as a therapy against 
inflammatory diseases, including Behçet’s disease, inflammatory bowel disease, multiple sclerosis, 
experimental sepsis and inflammatory polyarthritis [30–38]. IVIG therapy has been reported to be 
effective for reducing the incidence of coronary artery lesions in KD patients [39–41]. However, at 
least 10% of KD patients fail to exhibit defervescence with IVIG therapy [19,20]. Some reports have 
recommended alternative anti-inflammatory therapies with steroids, and recently, with ulinastatin 
and infliximab, for the treatment of KD [42–46]. In this study 1 ,25-(OH)2D3 exhibits 
anti-inflammatory effects after TNF-  stimulation (from 4 h onwards). In addition, the inhibitory 
effects of 1 ,25-(OH)2D3 in VCAM-1 expression were seen 4h after TNF-  stimulation. We 
therefore believe that 1 ,25-(OH)2D3 may inhibit HCAECs activation by TNF-  in the acute phase 
of KD temporarily. Our present results suggest that adjunctive 1 ,25-(OH)2D3 therapy may modulate 
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the inflammatory response during KD vasculitis, particularly during the acute phase. Importantly, 
1 ,25-(OH)2D3 has been widely used in children and has a high safety index and few side effects. 
5. Conclusion  
The present study showed that 1 ,25-(OH)2D3 inhibited TNF- –induced surface expression of 
VCAM-1 and production of IL-8 in HCAECs. The findings suggesting that adjunctive 
1 ,25-(OH)2D3 therapy may modulate the inflammatory response during KD vasculitis.
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7. Figure Legends
Figure 1. 1 ,25-(OH)2D3 inhibits VCAM-1 expression in TNF- –treated HCAECs.  
The expression of VCAM-1 in HCAECs was measured by flow cytometry. HCAECs were 
pretreated with 10-7, 10-8 and 10-9 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-  for 
4 h. *p < 0.05, compared to cells treated with TNF- . Data are presented as the mean ± SD. 
Figure 2. The kinetics of VCAM-1 expression on HCAECs pretreated with 1 ,25-(OH)2D3. 
HCAECs were pretreated with 10-8 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-
for 0, 4, 8, 12, and 24 h. White bars indicate cells stimulated by TNF-  only and black bars indicate 
cells pretreated with 10-8 M 1 ,25-(OH)2D3 prior to stimulation with TNF- . Data are presented as 
the mean ± SD with *p < 0.05, compared to cells treated with TNF- . 
Figure 3. 1 ,25-(OH)2D3 inhibition of ICAM-1 expression in TNF- –treated HCAECs.  
The surface expression of ICAM-1 in HCAECs was measured by flow cytometry. HCAECs were 
pretreated with 10-7, 10-8, and 10-9 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-  for 
4 h. Data are presented as the mean ± SD.  
Figure 4. Inhibitory effect of 1 ,25-(OH)2D3 on IL-8 production in TNF- –treated HCAECs.  
IL-8 production in HCAECs was measured by ELISA. HCAECs were pretreated with 10-7, 10-8, and 
10-9 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-  for 24h. The data are expressed 
as the ratio of stimulated cells to cells cultured in medium alone. Data are presented as the mean ± 
SD with *p < 0.05, compared to cells treated with TNF- . 
Figure 5. Kinetics of IL-8 production on HCAECs pretreated with 1 ,25-(OH)2D3.  
HCAECs were pretreated with 10-8 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-
for 0, 4, 8, 12, and 24 h. White bars indicate cells stimulated by TNF-  only, and black bars indicate 
cells pretreated with 10-8 M 1 ,25-(OH)2D3 stimulated by TNF- . Data are presented as the mean ± 
SD with **p < 0.01 and * p <0.05, compared to cells treated with TNF-  only.  
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Figure 6. Inhibitory effect of 1 ,25-(OH)2D3 on IL-6 production in TNF- –treated HCAECs.  
IL-6 production in HCAECs was measured by ELISA. HCAECs were pretreated with 10-7, 10-8, and 
10-9 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-  for 24h. Data are presented as the 
mean ± SD. 
Figure 7. 1 ,25-(OH)2D3 inhibits VCAM-1 mRNA expression in TNF- –treated HCAECs.  
The mRNA expression of VCAM-1 in HCAECs was measured by real-time PCR. HCAECs were 
pretreated with 10-7, 10-8 and 10-9 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-  for 
2h (white bar), 4 h (gray bar) and 8h (black bar). The data are expressed as the ratio of stimulated 
cells to cells cultured in medium alone. *p < 0.05, compared to cells treated with TNF- . Data are 
presented as the mean ± SD. 
Figure 8. Inhibitory effect of 1 ,25-(OH)2D3 on IL-8 mRNA expression in TNF- –treated HCAECs.  
IL-8 mRNA expression in HCAECs was measured by real-time PCR. HCAECs were pretreated 
with 10-7, 10-8, and 10-9 M 1 ,25-(OH)2D3 for 30 min prior to stimulation with TNF-  for 2h (white 
bar), 4 h (gray bar) and 8h (black bar). The data are expressed as the ratio of stimulated cells to cells 
cultured in medium alone. Data are presented as the mean ± SD with *p < 0.05, compared to cells 
treated with TNF- . 
